Nitz U, Gluz O, Graeser M, Christgen M, et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase Lancet Oncol 2022 Apr 8. pii: S1470-2045(22)00159.
PMID: 35405088